[Risk-benefit analysis of intra-arterial and intravenous PGE1 infusions in peripheral arterial occlusive disorders].
On the basis of pharmacological and clinical studies this review describes the effects of prostaglandin E1 (PGE1) on the cardiopulmonary system and its profile of adverse reactions taking into account spontaneous reports of side effects. All in all no increased risk of cardiovascular adverse reactions was obvious. PGE1 rather showed some desirable effects on heart and lung. Thus the analysis revealed a positive risk benefit relation for PGE1, provided that dosage and contra-indications are not neglected.